<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02800954</url>
  </required_header>
  <id_info>
    <org_study_id>AOL08-DR-SALLE</org_study_id>
    <nct_id>NCT02800954</nct_id>
  </id_info>
  <brief_title>Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma</brief_title>
  <acronym>MCSF-MYELOME</acronym>
  <official_title>Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Primary objective of this study is to compare serum levels of Macrophage-Colony
      Stimulating Factor (M-CSF) in a population of patients with multiple myeloma (MM), in a
      population of patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and in
      a control population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Macrophage-Colony Stimulating Factor (M-CSF) levels</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumour osteolysis</measure>
    <time_frame>Day 1</time_frame>
    <description>determined by the presence of osteolytic lesions, osteopenia or pathological fractures, presence of bone pain</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>multiple myeloma group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>case group = patients with multiple myeloma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MGUS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>monoclonal gammopathy of undetermined significance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>control group = healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <arm_group_label>multiple myeloma group</arm_group_label>
    <arm_group_label>MGUS group</arm_group_label>
    <arm_group_label>healthy control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bone marow samples</intervention_name>
    <arm_group_label>multiple myeloma group</arm_group_label>
    <arm_group_label>MGUS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For the multiple myeloma group

          -  confirmed diagnosis of de novo multiple myeloma according to the International Myeloma
             Working Group criteria

          -  bisphosphonate therapy for more than 60 days,

          -  signature of the informed consent form,

          -  patients over the age of 18 years. For the monoclonal gammopathy of undetermined
             significance (MGUS) group

          -  confirmed diagnosis of MGUS according to the International Myeloma Working Group
             criteria

          -  signature of the informed consent form,

          -  patients over the age of 18 years. For the healthy control group

          -  signature of the informed consent form,

          -  subjects over the age of 18 years.

        Exclusion Criteria:

          -  patients with thyroid or parathyroid disease,

          -  osteomalacia, rheumatoid arthritis, Paget's disease, osteoporosis,

          -  bisphosphonate therapy for less than 60 days,

          -  absence of informed consent,

          -  patients under the age of 18 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valéry SALLE, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valéry SALLE, PhD</last_name>
    <phone>+33 3 22 66 88 22</phone>
    <email>Salle.Valery@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valéry SALLE, PhD</last_name>
      <phone>03 22 66 88 22</phone>
      <email>Salle.Valery@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc DUTEL, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Saint Quentin</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reda GARIDI, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>bone lesions</keyword>
  <keyword>Macrophage-Colony Stimulating Factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

